Cargando…

Revealing the prognostic and clinicopathological significance of systemic immune-inflammation index in patients with different stage prostate cancer: A systematic review and meta-analysis

BACKGROUND: A novel inflammatory marker called the systemic immune-inflammation index (SII) was applied to predict the prognosis of different cancers. However, the role of SII in prostate cancer (PCa) remains unclear. This systematic review aims to explore the prognostic role of SII in different sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Qi, Wenqiang, Zhou, Yongheng, Liu, Zhifeng, Wang, Jian, Lv, Guangda, Zhong, Minglei, Wang, Wenfu, Li, Rongyang, Chen, Shouzhen, Shi, Benkang, Zhu, Yaofeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659961/
https://www.ncbi.nlm.nih.gov/pubmed/36388917
http://dx.doi.org/10.3389/fmed.2022.1052943
_version_ 1784830317847117824
author Qi, Wenqiang
Zhou, Yongheng
Liu, Zhifeng
Wang, Jian
Lv, Guangda
Zhong, Minglei
Wang, Wenfu
Li, Rongyang
Chen, Shouzhen
Shi, Benkang
Zhu, Yaofeng
author_facet Qi, Wenqiang
Zhou, Yongheng
Liu, Zhifeng
Wang, Jian
Lv, Guangda
Zhong, Minglei
Wang, Wenfu
Li, Rongyang
Chen, Shouzhen
Shi, Benkang
Zhu, Yaofeng
author_sort Qi, Wenqiang
collection PubMed
description BACKGROUND: A novel inflammatory marker called the systemic immune-inflammation index (SII) was applied to predict the prognosis of different cancers. However, the role of SII in prostate cancer (PCa) remains unclear. This systematic review aims to explore the prognostic role of SII in different stage PCa. METHODS: We comprehensively searched three public databases: PubMed, EMBASE, and the Cochrane Library. The hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were extracted to evaluate the association between SII and the prognosis and clinicopathological characteristics in different stage PCa patients. RESULTS: Ten studies and 7,986 patients were enrolled in our meta-analysis, 1,442 patients were diagnosed with metastatic-castration resistant prostate cancer (mCRPC), and 6544 patients were diagnosed with non-metastatic prostate cancer (nmPCa). According to the pooled results, we found that a high SII was associated with worse overall survival (OS) in mCRPC patients (HR = 1.94, 95% CI: 1.26–3.01, p = 0.003), and a high SII was associated with biochemical recurrence-free survival (BFS) in nmPCa patients (HR = 1.85, 95% CI: 1.06–3.24, p = 0.031). But there was no significant association observed between SII and progression-free survival (PFS) in mCRPC patients (HR = 1.90, 95% CI: 0.87–4.14, p = 0.107). And we found that the high SII was associated with advanced tumor stage of PCa (OR = 2.19, 95% CI: 1.11–4.33, p = 0.024), presence of lymph node involvement (OR = 2.72, 95% CI: 1.96–3.76, p < 0.001) and Gleason score (OR = 1.27, 95% CI: 1.13–1.44, p < 0.001). CONCLUSION: High SII was associated with bad OS in mCRPC patients, and associated with bad BFS and some adverse pathological features in nmPCa patients. We think SII can be a prognostic predictor for PCa patients. The application of SII will advance the diagnosis and treatment of different stage prostate cancer.
format Online
Article
Text
id pubmed-9659961
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96599612022-11-15 Revealing the prognostic and clinicopathological significance of systemic immune-inflammation index in patients with different stage prostate cancer: A systematic review and meta-analysis Qi, Wenqiang Zhou, Yongheng Liu, Zhifeng Wang, Jian Lv, Guangda Zhong, Minglei Wang, Wenfu Li, Rongyang Chen, Shouzhen Shi, Benkang Zhu, Yaofeng Front Med (Lausanne) Medicine BACKGROUND: A novel inflammatory marker called the systemic immune-inflammation index (SII) was applied to predict the prognosis of different cancers. However, the role of SII in prostate cancer (PCa) remains unclear. This systematic review aims to explore the prognostic role of SII in different stage PCa. METHODS: We comprehensively searched three public databases: PubMed, EMBASE, and the Cochrane Library. The hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were extracted to evaluate the association between SII and the prognosis and clinicopathological characteristics in different stage PCa patients. RESULTS: Ten studies and 7,986 patients were enrolled in our meta-analysis, 1,442 patients were diagnosed with metastatic-castration resistant prostate cancer (mCRPC), and 6544 patients were diagnosed with non-metastatic prostate cancer (nmPCa). According to the pooled results, we found that a high SII was associated with worse overall survival (OS) in mCRPC patients (HR = 1.94, 95% CI: 1.26–3.01, p = 0.003), and a high SII was associated with biochemical recurrence-free survival (BFS) in nmPCa patients (HR = 1.85, 95% CI: 1.06–3.24, p = 0.031). But there was no significant association observed between SII and progression-free survival (PFS) in mCRPC patients (HR = 1.90, 95% CI: 0.87–4.14, p = 0.107). And we found that the high SII was associated with advanced tumor stage of PCa (OR = 2.19, 95% CI: 1.11–4.33, p = 0.024), presence of lymph node involvement (OR = 2.72, 95% CI: 1.96–3.76, p < 0.001) and Gleason score (OR = 1.27, 95% CI: 1.13–1.44, p < 0.001). CONCLUSION: High SII was associated with bad OS in mCRPC patients, and associated with bad BFS and some adverse pathological features in nmPCa patients. We think SII can be a prognostic predictor for PCa patients. The application of SII will advance the diagnosis and treatment of different stage prostate cancer. Frontiers Media S.A. 2022-10-31 /pmc/articles/PMC9659961/ /pubmed/36388917 http://dx.doi.org/10.3389/fmed.2022.1052943 Text en Copyright © 2022 Qi, Zhou, Liu, Wang, Lv, Zhong, Wang, Li, Chen, Shi and Zhu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Qi, Wenqiang
Zhou, Yongheng
Liu, Zhifeng
Wang, Jian
Lv, Guangda
Zhong, Minglei
Wang, Wenfu
Li, Rongyang
Chen, Shouzhen
Shi, Benkang
Zhu, Yaofeng
Revealing the prognostic and clinicopathological significance of systemic immune-inflammation index in patients with different stage prostate cancer: A systematic review and meta-analysis
title Revealing the prognostic and clinicopathological significance of systemic immune-inflammation index in patients with different stage prostate cancer: A systematic review and meta-analysis
title_full Revealing the prognostic and clinicopathological significance of systemic immune-inflammation index in patients with different stage prostate cancer: A systematic review and meta-analysis
title_fullStr Revealing the prognostic and clinicopathological significance of systemic immune-inflammation index in patients with different stage prostate cancer: A systematic review and meta-analysis
title_full_unstemmed Revealing the prognostic and clinicopathological significance of systemic immune-inflammation index in patients with different stage prostate cancer: A systematic review and meta-analysis
title_short Revealing the prognostic and clinicopathological significance of systemic immune-inflammation index in patients with different stage prostate cancer: A systematic review and meta-analysis
title_sort revealing the prognostic and clinicopathological significance of systemic immune-inflammation index in patients with different stage prostate cancer: a systematic review and meta-analysis
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9659961/
https://www.ncbi.nlm.nih.gov/pubmed/36388917
http://dx.doi.org/10.3389/fmed.2022.1052943
work_keys_str_mv AT qiwenqiang revealingtheprognosticandclinicopathologicalsignificanceofsystemicimmuneinflammationindexinpatientswithdifferentstageprostatecancerasystematicreviewandmetaanalysis
AT zhouyongheng revealingtheprognosticandclinicopathologicalsignificanceofsystemicimmuneinflammationindexinpatientswithdifferentstageprostatecancerasystematicreviewandmetaanalysis
AT liuzhifeng revealingtheprognosticandclinicopathologicalsignificanceofsystemicimmuneinflammationindexinpatientswithdifferentstageprostatecancerasystematicreviewandmetaanalysis
AT wangjian revealingtheprognosticandclinicopathologicalsignificanceofsystemicimmuneinflammationindexinpatientswithdifferentstageprostatecancerasystematicreviewandmetaanalysis
AT lvguangda revealingtheprognosticandclinicopathologicalsignificanceofsystemicimmuneinflammationindexinpatientswithdifferentstageprostatecancerasystematicreviewandmetaanalysis
AT zhongminglei revealingtheprognosticandclinicopathologicalsignificanceofsystemicimmuneinflammationindexinpatientswithdifferentstageprostatecancerasystematicreviewandmetaanalysis
AT wangwenfu revealingtheprognosticandclinicopathologicalsignificanceofsystemicimmuneinflammationindexinpatientswithdifferentstageprostatecancerasystematicreviewandmetaanalysis
AT lirongyang revealingtheprognosticandclinicopathologicalsignificanceofsystemicimmuneinflammationindexinpatientswithdifferentstageprostatecancerasystematicreviewandmetaanalysis
AT chenshouzhen revealingtheprognosticandclinicopathologicalsignificanceofsystemicimmuneinflammationindexinpatientswithdifferentstageprostatecancerasystematicreviewandmetaanalysis
AT shibenkang revealingtheprognosticandclinicopathologicalsignificanceofsystemicimmuneinflammationindexinpatientswithdifferentstageprostatecancerasystematicreviewandmetaanalysis
AT zhuyaofeng revealingtheprognosticandclinicopathologicalsignificanceofsystemicimmuneinflammationindexinpatientswithdifferentstageprostatecancerasystematicreviewandmetaanalysis